Granted Patent
B2
US 12,486,505 · App. 18/305,195 · Granted Dec 2, 2025
Oligonucleotide compositions and methods thereof
Inventors:
Maria David Frank-Kamenetsky (Brookline, MA); Hailin Yang (West Roxbury, MA); Aaron Jay Morris (Brighton, MA); Chandra Vargeese (Schwenksville, PA); Christopher J. Francis (Carlisle, MA)
Assignee:
WAVE LIFE SCIENCES LTD.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Among other things, the present disclosure relates to designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide altered splicing of a transcript. In some embodiments, provided oligonucleotide compositions have low toxicity. In some embodiments, provided oligonucleotide compositions provide improved protein binding profiles. In some embodiments, provided oligonucleotide compositions have improved delivery. In some embodiments, provided oligonucleotide compositions have improved uptake. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions.
Claims (27)
1 . A method for identifying a chirally controlled oligonucleotide composition that has reduced complement activation relative to a reference oligonucleotide composition, the method comprising:
providing at least one chirally controlled oligonucleotide composition comprising a plurality of oligonucleotides;
assessing complement activation of each of the at least one chirally controlled oligonucleotide composition relative to the reference oligonucleotide composition; and
identify a chirally controlled oligonucleotide composition that displays reduced complement activation relative to the reference oligonucleotide composition;
wherein:
each of the at least one chirally controlled oligonucleotide composition is independently an oligonucleotide composition comprising a plurality of oligonucleotides of a particular oligonucleotide type which are structurally identical and is defined by:
1) base sequence;
2) pattern of backbone linkages;
3) pattern of backbone chiral centers; and
4) pattern of backbone phosphorus modifications;
which composition is chirally controlled in that it is enriched, relative to a substantially racemic preparation of oligonucleotides of the particular oligonucleotide type;
in the identified chirally controlled oligonucleotide composition, oligonucleotides of the plurality comprises 5 or more phosphorothioate internucleotidic linkages, wherein at least about 50% phosphorothioate internucleotidic linkages are Sp; and
the reference oligonucleotide composition is a substantially racemic preparation of oligonucleotides of the particular type.
2 . The method of claim 1 , wherein the reduced complement activation is observed in an assay that detects the presence, absolute level and/or relative level of C3a or Bb.
3 . The method of claim 1 , wherein the pattern of backbone chiral centers comprise at least one Rp and at least one Sp.
4 . The method of claim 3 , wherein the pattern of backbone chiral centers comprise Rp(Sp)m, wherein m is 2.
5 . The method of claim 4 , wherein the pattern of backbone chiral centers comprise Rp(Sp)m, wherein m is 3.
6 . The method of claim 4 , wherein the pattern of backbone chiral centers comprise Rp(Sp)m, wherein m is 4.
7 . The method of claim 4 , wherein the pattern of backbone chiral centers comprise Rp(Sp)m, wherein m is 5.
8 . The method of claim 4 , wherein the pattern of backbone chiral centers comprise Rp(Sp)m, wherein m is 6.
9 . The method of claim 4 , wherein the pattern of backbone chiral centers comprise Rp(Sp)m, wherein m is 7.
10 . The method of claim 4 , wherein the pattern of backbone chiral centers comprise Rp(Sp)m, wherein m is 8.
11 . The method of claim 4 , wherein the pattern of backbone chiral centers comprise RpSpSp.
12 . The method of claim 11 , wherein the pattern of backbone chiral centers comprise (Np)t(Rp)(Sp)m, wherein t is 1, m is 2, and each Np is independent Rp or Sp.
13 . The method of claim 12 , wherein the pattern of backbone chiral centers comprise SpRpSpSp.
14 . The method of claim 12 , wherein the pattern of backbone chiral centers comprise SpSpRpSpSp.
15 . The method of claim 4 , wherein oligonucleotides of the first plurality comprise one or more natural phosphate linkages.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 1, 2023
From: FRANK-KAMENETSKY, MARIA D.; YANG, HAILIN; MORRIS, AARON; VARGEESE, CHANDRA; FRANCIS, CHRISTOPHER J.
To: WAVE LIFE SCIENCES LTD.
Reel/Frame 063821/0597 →
Continuity (6)
Continuation
15746199
Provisional Application
62331960
· May 4, 2016
Provisional Application
62236847
· Oct 2, 2015
Provisional Application
62195779
· Jul 22, 2015
References Cited (327)
US 5212295A
· Cook
· 1993
[cited by applicant]
US 5521302A
· Cook
· 1996
[cited by applicant]
US 5587361A
· Cook et al.
· 1996
[cited by applicant]
US 5792615A
· Arnold, Jr. et al.
· 1998
[cited by applicant]
US 6146829A
· Cook et al.
· 2000
[cited by applicant]
US 6172209B1
· Manoharan et al.
· 2001
[cited by applicant]
US 6639022B2
· Michels et al.
· 2003
[cited by applicant]
US 6867294B1
· Sanghvi et al.
· 2005
[cited by applicant]
US 6949520B1
· Hartmann et al.
· 2005
[cited by applicant]
US RE39464E
· Cook et al.
· 2007
[cited by applicant]
US 7919472B2
· Monia et al.
· 2011
[cited by applicant]
US 7947658B2
· Aronin et al.
· 2011
[cited by applicant]
US 7951934B2
· Freier
· 2011
[cited by applicant]
US 8415465B2
· Freier
· 2013
[cited by applicant]
US 8470987B2
· Wada et al.
· 2013
[cited by applicant]
US 8481710B2
· Davidson et al.
· 2013
[cited by applicant]
US 8679750B2
· Hayden et al.
· 2014
[cited by applicant]
US 8680063B2
· Aronin et al.
· 2014
[cited by applicant]
US 8822671B2
· Shimizu et al.
· 2014
[cited by applicant]
US 8859755B2
· Wada et al.
· 2014
[cited by applicant]
US 8906873B2
· Hung et al.
· 2014
[cited by applicant]
US 8952145B2
· Freier
· 2015
[cited by applicant]
US 8987222B2
· Aronin et al.
· 2015
[cited by applicant]
US 9006198B2
· Bennett et al.
· 2015
[cited by applicant]
US 9057066B2
· Hung et al.
· 2015
[cited by applicant]
US 9260716B2
· Davidson et al.
· 2016
[cited by applicant]
US 9353372B2
· Freier
· 2016
[cited by applicant]
US 9394333B2
· Wada et al.
· 2016
[cited by applicant]
US 9476044B2
· Tuschl et al.
· 2016
[cited by applicant]
US 9598458B2
· Shimizu et al.
· 2017
[cited by applicant]
US 9605019B2
· Verdine et al.
· 2017
[cited by applicant]
US 9617547B2
· Gemba
· 2017
[cited by applicant]
US 9683236B2
· Hung et al.
· 2017
[cited by applicant]
US 9695211B2
· Wada et al.
· 2017
[cited by applicant]
US 9744183B2
· Verdine et al.
· 2017
[cited by applicant]
US 9982257B2
· Butler et al.
· 2018
[cited by applicant]
US 20020082227A1
· Henry
· 2002
[cited by applicant]
US 20020183502A1
· Mesmaeker et al.
· 2002
[cited by applicant]
US 20140303235A1
· Oestergaard et al.
· 2014
[cited by applicant]
US 20150292015A1
· Bennett et al.
· 2015
[cited by applicant]
US 20170130224A1
· Oestergaard et al.
· 2017
[cited by applicant]
US 20190264267A1
· Yang et al.
· 2019
[cited by applicant]
US 20200362337A1
· Dodart et al.
· 2020
[cited by applicant]
US 20220098585A1
· Brown et al.
· 2022
[cited by applicant]
US 20220145300A1
· Liu et al.
· 2022
[cited by applicant]
US 20220186217A1
· Zhang et al.
· 2022
[cited by applicant]
US 20220195429A1
· Vargeese et al.
· 2022
[cited by applicant]
US 20220307019A1
· Yokota et al.
· 2022
[cited by applicant]
US 20230136645A1
· Butler et al.
· 2023
[cited by applicant]
US 20230203087A1
· Kandasamy et al.
· 2023
[cited by applicant]
US 20230220384A1
· Monian et al.
· 2023
[cited by applicant]
US 20230295617A1
· Vargeese et al.
· 2023
[cited by applicant]
US 20230295619A1
· Maguire et al.
· 2023
[cited by applicant]
US 20230329201A1
· Yang et al.
· 2023
[cited by applicant]
US 20230392137A1
· Monian et al.
· 2023
[cited by applicant]
US 20240026358A1
· Monian et al.
· 2024
[cited by applicant]
US 20240109931A1
· Vargeese et al.
· 2024
[cited by applicant]
US 20240132894A1
· Vargeese et al.
· 2024
[cited by applicant]
US 20240175018A1
· Vargeese et al.
· 2024
[cited by applicant]
US 20240229026A1
· Butler et al.
· 2024
[cited by applicant]
US 20250051778A1
· Byrne et al.
· 2025
[cited by applicant]
EP 2873674A1
· 2015
[cited by applicant]
JP H06220083A
· 1994
[cited by applicant]
JP 2003238586A
· 2003
[cited by applicant]
JP 2011184318A
· 2011
[cited by applicant]
RU 2616283C2
· 2017
[cited by applicant]
WO WO9308296A1
· 1993
[cited by applicant]
WO WO9905160A2
· 1999
[cited by applicant]
WO WO2005014609A2
· 2005
[cited by applicant]
WO WO2005023828A1
· 2005
[cited by applicant]
WO WO2005027980A1
· 2005
[cited by applicant]
WO WO2005028494A1
· 2005
[cited by applicant]
WO WO2005070859A1
· 2005
[cited by applicant]
WO WO2005085272A1
· 2005
[cited by applicant]
WO WO2005092909A1
· 2005
[cited by applicant]
WO WO2005111057A2
· 2005
[cited by applicant]
WO WO2007131237A2
· 2007
[cited by applicant]
WO WO2007131238A2
· 2007
[cited by applicant]
WO WO2007134014A2
· 2007
[cited by applicant]
WO WO2007134181A2
· 2007
[cited by applicant]
WO WO2007136988A2
· 2007
[cited by applicant]
WO WO2007139190A1
· 2007
[cited by applicant]
WO WO2007143315A2
· 2007
[cited by applicant]
WO WO2007143316A2
· 2007
[cited by applicant]
WO WO2007143317A2
· 2007
[cited by applicant]
WO WO2007146511A2
· 2007
[cited by applicant]
WO WO2008049085A1
· 2008
[cited by applicant]
WO WO2010064146A2
· 2010
[cited by applicant]
WO WO2010091301A1
· 2010
[cited by applicant]
WO WO2011005761A1
· 2011
[cited by applicant]
WO WO2011034072A1
· 2011
[cited by applicant]
WO WO2011082281A2
· 2011
[cited by applicant]
WO WO2011108682A1
· 2011
[cited by applicant]
WO WO2012039448A1
· 2012
[cited by applicant]
WO WO2012073857A1
· 2012
[cited by applicant]
WO WO2012109395A1
· 2012
[cited by applicant]
WO WO2012145729A2
· 2012
[cited by applicant]
WO WO2013012758A1
· 2013
[cited by applicant]
WO WO2013022984A1
· 2013
[cited by applicant]
WO WO2013112053A1
· 2013
[cited by applicant]
WO WO2014010250A1
· 2014
[cited by applicant]
WO WO2014010718A1
· 2014
[cited by applicant]
WO WO2014012081A2
· 2014
[cited by applicant]
WO WO2014118267A1
· 2014
[cited by applicant]
WO WO2014121287A2
· 2014
[cited by applicant]
WO WO2014179626A2
· 2014
[cited by applicant]
WO WO2015051214A1
· 2015
[cited by applicant]
WO WO2015107425A2
· 2015
[cited by applicant]
WO WO2015108046A1
· 2015
[cited by applicant]
WO WO2015108047A1
· 2015
[cited by applicant]
WO WO2015108048A1
· 2015
[cited by applicant]
WO WO2016079181A1
· 2016
[cited by applicant]
WO WO2016096938A1
· 2016
[cited by applicant]
WO WO2016127000A1
· 2016
[cited by applicant]
WO WO2017015555A1
· 2017
[cited by applicant]
WO WO2017015575A1
· 2017
[cited by applicant]
WO WO2017062862A2
· 2017
[cited by applicant]
WO WO2017067970A1
· 2017
[cited by applicant]
WO WO2017160741A1
· 2017
[cited by applicant]
WO WO2017192664A1
· 2017
[cited by applicant]
WO WO2017192679A1
· 2017
[cited by applicant]
WO WO2017210647A1
· 2017
[cited by applicant]
WO WO2018022473A1
· 2018
[cited by applicant]
WO WO2018067973A1
· 2018
[cited by applicant]
WO WO2018098264A1
· 2018
[cited by applicant]
WO WO2018223056A1
· 2018
[cited by applicant]
WO WO2018223073A1
· 2018
[cited by applicant]
WO WO2018223081A1
· 2018
[cited by applicant]
WO WO2018237194A1
· 2018
[cited by applicant]
WO WO2019032607A1
· 2019
[cited by applicant]
WO WO2019032612A1
· 2019
[cited by applicant]
WO WO2019055951A1
· 2019
[cited by applicant]
WO WO2019075357A1
· 2019
[cited by applicant]
WO WO2019200185A1
· 2019
[cited by applicant]
WO WO2019217784A1
· 2019
[cited by applicant]
WO WO2020118246A1
· 2020
[cited by applicant]
WO WO2020160336A1
· 2020
[cited by applicant]
WO WO2020191252A1
· 2020
[cited by applicant]
WO WO2020196662A1
· 2020
[cited by applicant]
WO WO2020219981A2
· 2020
[cited by applicant]
WO WO2020219983A2
· 2020
[cited by applicant]
WO WO2020227691A2
· 2020
[cited by applicant]
WO WO2021071788A2
· 2021
[cited by applicant]
WO WO2021071858A1
· 2021
[cited by applicant]
WO WO2021178237A2
· 2021
[cited by applicant]
WO WO2021234459A2
· 2021
[cited by applicant]
WO WO2021237223A1
· 2021
[cited by applicant]
WO WO2022046667A1
· 2022
[cited by applicant]
WO WO2022046723A1
· 2022
[cited by applicant]
WO WO2022099159A1
· 2022
[cited by applicant]
WO WO2023049475A1
· 2023
[cited by applicant]
WO WO2023049477A2
· 2023
[cited by applicant]
WO WO2023075766A1
· 2023
[cited by applicant]
WO WO2023076352A2
· 2023
[cited by applicant]
WO WO2023154528A1
· 2023
[cited by applicant]
WO WO2023168014A2
· 2023
[cited by applicant]
WO WO2023201095A2
· 2023
[cited by applicant]
WO WO2023220440A1
· 2023
[cited by applicant]
WO WO2024035946A1
· 2024
[cited by applicant]
WO WO2025030155A1
· 2025
[cited by applicant]
U.S. Appl. No. 17/605,998, filed Oct. 22, 2021, Byrne et al.
[cited by applicant]
U.S. Appl. No. 17/766,680, filed Apr. 5, 2022, Liu et al.
[cited by applicant]
U.S. Appl. No. 17/953,292, filed Sep. 26, 2022, Monian et al.
[cited by applicant]
U.S. Appl. No. 17/956,741, filed Sep. 29, 2022, Vargeese et al.
[cited by applicant]
U.S. Appl. No. 17/960,090, filed Oct. 4, 2022, Vargeese et al.
[cited by applicant]
U.S. Appl. No. 18/062,422, filed Dec. 6, 2022, Butler et al.
[cited by applicant]
U.S. Appl. No. 18/178,470, filed Mar. 3, 2023, Vargeese et al.
[cited by applicant]
U.S. Appl. No. 18/204,895, filed Jun. 1, 2023, Vargeese et al.
[cited by applicant]
U.S. Appl. No. 18/252,029, filed May 5, 2023, Monian et al.
[cited by applicant]
U.S. Appl. No. 18/316,932, filed May 12, 2023, Butler et al.
[cited by applicant]
Agrawal, S. et al., Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies, Proc. Natl. Acad. Sci. USA, 94: 2620-2625 (1997).
[cited by applicant]
Bilesen, P.H.J. et al., Identification and Allele-Specific Silencing of the Mutant Huntingtin Allele in Huntington's Disease Patient-Derived Fibroblasts, Hum. Gene Thera., 19:710-718 (2008).
[cited by applicant]
Bock, L.C. et al., Selections of single-stranded DNA molecules that bind and inhibit human thrombin, Nature, 355: 564-566 (1992).
[cited by applicant]
Boyanapalli, R. et al., A Novel Quantitative Wild-type Huntingtin (wtHTT) Protein Biomarker Method for Human Cerebrospinal Fluid, Wave Life Sciences, presented at the 17th Annual Huntington's Disease Therapeutics Confer…
[cited by applicant]
Carroll, J. B. et al., Potent and Selective Antisense Oligonucleotides Targeting Single-Nucleotide Polymorphisms in the Huntington Disease Gene / Allele-Specific Silencing of Mutant Huntingtin, Mol. Thera., 19(12):2178-…
[cited by applicant]
Chan, J.H.P. et al., Antisense Oligonucleotides: From Design to Therapeutic Application, Clinical and Experimental Pharmacology and Physiology, 33: 544-540 (2006).
[cited by applicant]
Crooke, S. T., Antisense Drug Technology: Principles, Strategies, and Applications, 2nd Edition, pp. 1-66 (2008).
[cited by applicant]
Crooke, S. T., Antisense Strategies, Curr. Mol. Med., 4(5):465-487 (2004).
[cited by applicant]
Crooke, S.T., Progress in Antisense Technology , Annu. Rev. Med., 55: 61-95 (2004).
[cited by applicant]
Dale, E., Enhancing the pharmacologic profiles of CNS targeting therapeutic oligonucleotides, Wave Life Sciences, presented at TIDES USA, on Sep. 23, 2021.
[cited by applicant]
Engelhardt, J.A. et al., Scientific and Regulatory Policy Committee Points-to-consider Paper: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part 2. Antisense Oli…
[cited by applicant]
Frazier, K. et al., Potential Mechanisms of vascular toxicity in Monkeys with antisense oligonucleotides, TIDES oligo conference, 1-25 (May 15, 2014).
[cited by applicant]
Frazier, K.S. Antisense Oligonucleotide Therapies: The Promise and the Challenges from a Toxicologic Pathologist's Perspective, Toxicology Pathology, 43: 78-89 (2015).
[cited by applicant]
Gagnon, K. T. et al., Allele-Selective Inhibitions of Mutant Huntingtin Expression with Antisense Oligonucleotide Targeting the Expanded CAG Repeat, Biochemistry 49(47): 10166-10178 (2010).
[cited by applicant]
Gagnon, K.T. and Watts, J.K 10th Annual Meeting of the Oligonucleotide Therapeutics Society, San Diego, CA, Summer Summaries (Oct. 12-15, 2014).
[cited by applicant]
Hartmann, G. et al., Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo, The Journal of Immunology, 164(3): 1617-1624 (2000).
[cited by applicant]
Henry, S.P. et al., Activation of the Alternative Pathway of Complement by a Phosphorothioate Oligonucleotide: Potential Mechanism of Action, The Journal of Pharmacology and Experimental Therapeutics, 281(2): 810-816 (1…
[cited by applicant]
Hu, J. et al., Allele-Selective Inhibition of Huntingtin Expression by Switching to an miRNA-like RNAi Mechanism, Chemistry & Biology 17: 1183-1188 (2010).
[cited by applicant]
Hu, J. et al., Exploring the Effect of Sequence Length and Composition on Allele-Selective Inhibition of Human Huntingtin Expression by Single-Stranded Silencing RNAs, Nucleic Acid Therapeutics, 24(3): 199-209 (2014).
[cited by applicant]
Hung, S. Stereopure oligonucleotides as a therapeutic approach to rare neurological diseases. Paper presented at: Huntington's Society of Canada 2017 National Conference (Nov. 2017).
[cited by applicant]
International Search Report for PCT/US2016/043598, 4 pages (Nov. 28, 2016).
[cited by applicant]
Ionis Pharmaceuticals, Inc., Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with Huntington's Disease, Press Release, 2 pages (Dec. 11, 2017).
[cited by applicant]
Iwamoto, N. et al., Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides, Nature Biotechnol, 35(9): 845-851 (2017), with Supplemental Data, 14 pages.
[cited by applicant]
Iwamoto, N. et al., Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides, Nature Biotechnology, 1-7 pages (2017). All Supplemental Data, 8-53 pages (2017).
[cited by applicant]
Iwamoto, N. et al., Optimization of Therapeutic Phosphorothioate Oligonucleotides by P-Chirality Control, WAVE Life Sciences, PSJ Congress: The Pharmaceutical Society of Japan, (Mar. 25, 2015-Mar. 28, 2016).
[cited by applicant]
Iwamoto, N. From Stereopurity to precision medicine: Optimizing the properties of antisense nucleic acid therapeutics. Paper presented at: BioJapan, Yokohama, Japan (Oct. 11, 2018).
[cited by applicant]
Kandasamy, P. et al., From stereopurity to precision medicine: Optimizing the properties of antisense nucleic acid therapeutics. Paper presented at: the 45th International Symposium on Nucleic Acid Chemistry, Kyoto, Jap…
[cited by applicant]
Kaur, H. et al., Activation of natural killer-like YT-INDY cells by oligodeoxynucleotides and binding by homologous pattern recognition proteins, Scandinavian Journal of Immunology, 62: 361-370 (2005).
[cited by applicant]
Kay, C. et al., Personalized gene silencing therapeutics for Huntington disease, Clinical Genetics, 1-8 (2014).
[cited by applicant]
Koziolkewicz et al., Stability of Stereoregular Oligo-(nucleoside Phosphorothioate)s in Human Plasma: Diastereoselectiviy of Plasma 3′-Exonuclease, Antisense Nucl. Acid Drug Dev., 7: 43-48 (1997).
[cited by applicant]
Koziolkiewicz, M. et al., Effect of P-chirality of oligo(deoxyribonucleoside phosphorothioate)s) on the activity of terminal deoxyribonucleotidyl transferase, FEBS Letters, 434(1-2): 77-82 (1998).
[cited by applicant]
Krakowiak, A. et al., Influence of P-Chirality of Phosphorothioate Oligonucleotides on the Activity of Amv-Reverse Transcriptase, Nucleosides & Nucleotides, 17(9-11): 1823-1834 (1998).
[cited by applicant]
Krieg, A.M. et al., P-Chirality-Dependent Immune Activiation by Phosphorothioate CpG Oligodeoxynucleotides, Oligonucleotides, 13:491-499 (2003).
[cited by applicant]
Leviten, M., Wave's Purity Progress, Biocentury, 1-6 (Sep. 28, 2017).
[cited by applicant]
Liu, Y. et al., Impact of Nitrogen-containing Backbone Linkages on Stereopure Antisense Oligonucleotides in the CNS, Wave Life Sciences, Presented at TIDES USA: Oligonucleotide & Peptide Therapeutics on Sep. 20-23, 2021…
[cited by applicant]
McBride, J.L. et al., Prelinical Safety of RNAi-Mediated HTT Suppression in the Rhesus Macaque as a Potential Therapy for Huntington's Disease, Molecular Therapy, 19: 1-11 (2011).
[cited by applicant]
Meena, Control of Human RNase H Mediated Cleavage by Stereopure Phosphorothioate Oligonucleotides, WAVE Life Sciences, TIDES Meeting, 23 pages (May 3-6, 2015).
[cited by applicant]
Meena, Development of Allele Specific Antisense Oligonucleotides, WAVE Life Sciences, ACS Central Regional Meeting (CERM), Covington, KY (May 19, 2016).
[cited by applicant]
Meena, Development of Allele Specific Antisense Oligonucleotides, WAVE Life Sciences, TIDES Meeting (May 11, 2016).
[cited by applicant]
Meena, et al., Discovery and Early Clinical Development of the First Allele-Specific Stereopure ASO Drug Candidate with Disease—Modifying Potential for the Treatment of Huntington's Disease, WAVE Life Sciences, Poster, …
[cited by applicant]
Meena, et al., Therapeutic Implications of Controlling P-Chirality in Phosphorothioate Oligonucleotides, TIDES Poster (May 12-15, 2014).
[cited by applicant]
Meena, et al., Therapeutic Implications of Controlling P-Chirality in Phosphorothioate Oligonucleotides, TIDES, San Diego, WAVE Life Sciences, Poster, 1 page (May 3-6, 2014).
[cited by applicant]
Meena, Optimization of Antisense Drugs by P-Stereochemistry Control, WAVE Life Sciences, OTS Annual Meeting 2014, Oligonucleotide Therapeutics Society, 13 pages (Oct. 12-14, 2014).
[cited by applicant]
Midturi, J. et al., Spectrum of Pulmonary Toxicity Associated with the Use of Interferon Therapy for Hepatitis C: Case Report and Review of the Literature, Clinical Infectious Diseases, 39(11): 1724-1729 (2004).
[cited by applicant]
Miniarikova, J. et al., Design Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease, Molecular Therapy-Nucleic Acids, 5(3): e297 (2016).
[cited by applicant]
Mohapatra, S. LCMS/hybridization ELISA approaches for bioanalysis of stereopure oligonucleotides. Paper presented at: American Association of Pharmaceutical Scientists Annual Meeting, Washington, DC USA (Nov. 4-7, 2018).
[cited by applicant]
Mujeeb, A. et al., High-Resolution NMR of an Antisense DNA.RNA Hybrid Containing Alternating Chirally Pure R p Methylphosphonates in the DNA Backbone+, 36(9): 2371-2379 (1997).
[cited by applicant]
Ostergaard, M.E. et al., Differential effects on allele selective silencing of mutant huntingtin by two stereoisomers of α,β-constrained nucleic acid, ACS Chem. Biol., 9(9):1975-1979 (2014).
[cited by applicant]
Panzara, M. A. Stereopure Oligonucleotides in Development for the Treatment of Genetically Defined Diseases, Wave Life Sciences, presented at TIDES Boston Virtual Conference on Sep. 15-18, 2020.
[cited by applicant]
Panzara, M. et al., Stereopure nucleic acid therapies in development for the treatment of genetic neurological diseases, Poster presented at: 19th Annual Meeting of the American Society of Experimental Neurotherapeutics…
[cited by applicant]
Panzara, M. Stereopure nucleic acid therapies in development for the treatment of genetic neurological diseases, Neurotherapeutics, Abstract, 14: 821-822 (2017).
[cited by applicant]
Panzara, M. Stereopure nucleic acid therapies in development for the treatment of genetic neurological diseases, Paper presented at: 19th Annual Meeting of the American Society of Experimental Neurotherapeutics, Rockvil…
[cited by applicant]
Panzara, M. Stereopure nucleic acid therapies in development for the treatment of genetic neurological diseases. Paper presented at: International Society for CNS Drug Development (ISCDD) Annual Meeting, Las Vegas, NV U…
[cited by applicant]
Panzara, M., Innovations that led to SELECT-HD, a phase 1b/2a clinical trial of an allele-selective therapy for Huntington's Disease, Wave Life Sciences, presented on Mar. 3, 2022.
[cited by applicant]
Patil et al., Syntheses and properties of oligothymidylate analogs containing stereoregulated phosphorothioate and phosphodiester linkages in an alternating manner, Bioorganic & Medicinal Chemistry Letters, 4(22): 2663-…
[cited by applicant]
Pedersen, L. et al., A Kinetic Model Explains Why Shorter and Less Affine Enzyme-recruiting Oligonucleotides Can Be More Potent, Mol Ther Nucleic Acids, 3: e149 1-8 (2014).
[cited by applicant]
Pharmacology Review(s), Application No. 203568Orig1s000, Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health & Human Services, 2013.
[cited by applicant]
Pontarollo, R.A et al., Monocytes are required for optimum in vitro stimulation of bovine peripheral blood mononuclear cells by non-methylated CpG motifs, Veterinary Immunology and Immunopathology, 84(1-2): 43-59 (2002).
[cited by applicant]
Prakash, T.P. et al., 2′-O-[2-(Methylthio )ethyl]-Modified Oligonucleotide: An Analogue of 2′-O-[2-(Methoxy)-ethyl]-Modified Oligonucleotide with Improved Protein Binding Properties and High Binding Affinity to Target R…
[cited by applicant]
Robinson, D.S. et al., Predominant TH2-Like Bronchoalveolar T-Lymphocyte Population in Atopic Asthma, The New England Journal of Medicine, 326: 298-304 (1992).
[cited by applicant]
Senn, J.J. et al., Non-CpG-Containing Antisense 2′-Methoxyethyl Oligonucleotides Activate a Proinflammatory Response Independent of Toll-Like Receptor 9 or Myeloid DifferentiationFactor 88, The Journal of Pharmacology a…
[cited by applicant]
Seth, P., and Olson, R., Nucleic Acid Therapeutics—Making Sense of Antisesnse, 2016 Drug Design and Delivery Symposium, ACS Webinar, 1-36 (Jul. 26, 2016).
[cited by applicant]
Sheehan, J.P. and Phan, T.M. Phosphorothioate Oligonucleotides Inhibit the Intrinsic Tenase Complex by an Allosteric Mechanism, Biochemistry, 40: 4980-4989 (2001).
[cited by applicant]
Singhrao, S.K. et al., Increased Complement Biosynthesis by Microglia and Complement Activation on Neurons in Huntington's Disease, Experimental Neurology, 159: 362-376 (1999).
[cited by applicant]
Soldatow, V.Y. et al., In vitro models for liver toxicity testing, Toxicol Res, 2(1):23-39 (2013).
[cited by applicant]
Southwell, A. L. et al., In Vivo Evaluation of Candidate Allele-specific Mutant Huntingtin Gene Silencing Antisense Oligonucleotides, Mol. Thera., 22(12):2093-2106 (2014).
[cited by applicant]
Stec, W.J. et al., Deoxyribonucleoside 3′-O-(2-Thio- and 2-Oxo-“spiro”-4,4-pentamethylene-1,3,2-oxathiaphospholane)s: Monomers for Stereocontrolled Synthesis of Oligo(deoxyribonucleoside phosphorothioate)s and Chimeric …
[cited by applicant]
Tosquellas, G. et al., Prooligonucleotides exhibit less serum-protein binding than phosphodiester and phosphorothioate oligonucleotides, Nucleosides, Nucleotides and Nucleic Acids, 19(5-6):995-1003 (2000).
[cited by applicant]
Vargeese, C. From Stereopurity to precision medicine: Optimising the properties of antisense nucleic acid therapeutics, Paper presented at: TIDES Europe: Oligonucleotide and Peptide Therapeutics, Amsterdam, The Netherla…
[cited by applicant]
Vargeese, C. From Stereopurity to precision medicine: Optimizing the properties of antisense nucleic acid therapeutics, Paper presented at: Nature Conference on RNA at the Bench and Bedside, La Jolla, CA USA (Oct. 8, 20…
[cited by applicant]
Vargeese, C. Pharmacologic properties of stereopure oligonucleotides. Paper presented at: 44th International Symposium on Nucleic Acids Chemistry, Tokyo, Japan (Nov. 14-16, 2017).
[cited by applicant]
Vargeese, C. Stereochemical control of antisense oligonucleotides enhances target efficacy. Paper presented at: the 14th Annual Meeting of the Oligonucleotide Therapeutic Society, Seattle, WA USA (Oct. 3, 2018).
[cited by applicant]
Vergeese, C., Exploring new oligonucleotide backbone chemistries and their deployment to improve the properties of stereopure oligonucleotides, Wave Life Sciences, presented at TIDES USA on Sep. 22, 2021.
[cited by applicant]
Vickers, T. A. et al., Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents, Jrnl. Bio. Chem., 278(9):7108-7118 (2003).
[cited by applicant]
Viglietta, V., Select-HD: an adaptive first-in-human clinical trial to evaluate WVE-003, an investigational allele selective mHTT-lowering oligonucleotide, in early manifest Huntington's disease, Wave Life Sciences, pre…
[cited by applicant]
Wan, W.B. and Seth, P.P., The Medicinal Chemistry of Therapeutic Oligonucleotides, J. Med. Chem., 59: 9645-9667 (2016).
[cited by applicant]
Wan, W.B. et al., Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages, Nucleic Acid Research, 42(22):13456-13468 (2014). …
[cited by applicant]
WAVE Life Sciences, Second Quarter 2022 Earnings Presentation, 27 pages, (2022).
[cited by applicant]
WAVE Life Sciences, WAVE Life Sciences Corporate Presentation, 32 pages, Aug. 3, 2023.
[cited by applicant]
WAVE Life Sciences, WAVE Life Sciences Corporate Presentation, 63 pages, May 12, 2022.
[cited by applicant]
Woolf, T.M. et al., Specificity of antisense oligonucleotides in vivo, Prov. Natl. Aca. Sci. USA, 89: 7305-7309 (1992).
[cited by applicant]
Wozniak, L.A. et al., Chirality at phosphorus: hybrid duplexes of chimeric oligonucleotides containing methylphosphonothioate linkages with complementary DNA and RNA, Journal of Organometallic Chemistry, 690(10): 2658-2…
[cited by applicant]
Written Opinion for PCT/US2016/043598, 10 pages (Nov. 28, 2016).
[cited by applicant]
Xu, D. and Esko, J.D., Demystifying Heparan Sulfate- Protein Interactions, Annu. Rev. Biochem., 83: 129-157 (2014).
[cited by applicant]
Zhang, Y. et al., Structural Isosteres of Phosphate Groups in the Protein Data Bank, J. Chem. Inf. Model, 1-18 (2017).
[cited by applicant]
Zhang, Y., Investigating phosphate structural replacements through computational and experimental approaches, Academic Dissertain, University of Helsinki, 119 pages (2014).
[cited by applicant]
Zhong, Z. et al., WAVE Life Sciences: Developing Stereopure Nucleic Acid Therapies for the Treatment of Genetic Neurological Diseases, World CNS Summit 2017, Boston, MA, WAVE Life Sciences, Poster, 1 page (Feb. 20-22, 2…
[cited by applicant]
Zhong, Z. Stereochemical control of antisense oligonucleotides enhances target efficacy. Paper presented at: TIDES: Oligonucleotide and Peptide Therapeutics, Boston, MA USA (May 9, 2018).
[cited by applicant]
Zhong, Z. WAVE Life Sciences: Developing stereopure nucleic acid therapies for the treatment of serious genetically defined diseases, Paper presented at: ALS Drug Discovery Roundtable Meeting, Boston, MA (Apr. 25, 2017).
[cited by applicant]
Zon, Automated synthesis of phosphorus-sulfur analogs of nucleic acids—25 years on: potential therapeutic agents and proven utility in biotechnology, New J. Chem., 34(5): 795-804 (2010).
[cited by applicant]
U.S. Appl. No. 18/522,146, filed Nov. 28, 2023, Butler et al.
[cited by applicant]
U.S. Appl. No. 18/613,034, filed Mar. 21, 2024, Vargeese et al.
[cited by applicant]
U.S. Appl. No. 18/695,346, filed Mar. 25, 2024, Monian et al.
[cited by applicant]
U.S. Appl. No. 18/695,348, filed Mar. 25, 2024, Acker et al.
[cited by applicant]
U.S. Appl. No. 18/704,629, filed Apr. 25, 2024, Byrne et al.
[cited by applicant]
U.S. Appl. No. 18/836,993, filed Aug. 8, 2024, Kandasamy et al.
[cited by applicant]
U.S. Appl. No. 18/843,171, filed Aug. 30, 2024, Hu et al.
[cited by applicant]
U.S. Appl. No. 18/856,553, filed Oct. 11, 2024, Lu et al.
[cited by applicant]
U.S. Appl. No. 18/864,860, filed Nov. 11, 2024, Shivalila et al.
[cited by applicant]
U.S. Appl. No. 18/864,863, filed Nov. 11, 2024, Liu et al.
[cited by applicant]
U.S. Appl. No. 18/942,334, filed Nov. 8, 2024, Yang et al.
[cited by applicant]
U.S. Appl. No. 18/953,020, filed Nov. 19, 2024, Meena et al.
[cited by applicant]
U.S. Appl. No. 19/008,522, filed Jan. 2, 2025, Vargeese et al.
[cited by applicant]
Wang, L. et al., Phosphorothioation of DNA in bacteria by dnd genes, Nat. Chem. Biol., 3(11):709-710 (2007).
[cited by applicant]
Cited By (2)